In Anticipation Of Acquisition, Resverlogix Spins Out Epigenetics Platform
This article was originally published in The Pink Sheet Daily
Executive Summary
The publicly listed Canadian biotech is prepping for a potential takeout after Phase IIb for its lead candidate by spinning out its preclinical epigenetics platform into a new private company. If Resverlogix is acquired, the newco could potentially gain a royalty from the acquirer in exchange for access to IP.